They had about 385MM shares prior to the Alpha Biologics transaction. I believe about 180MM was controlled by INTAS. 525MM for Alpha puts us in the ballpark of 910MM, leaving approx 90MM authorized left. Rough numbers.
The company, like most startups in this industry does not have cash to make aquisitions which is why stock is leveraged.
News 
Market Data 
Discover 
